PAREXEL

PAREXEL is a multinational company operating in the pharmaceutical, biomedical engineering, and healthcare industries . The company was founded on January 1, 1982, and is headquartered in Newton, Massachusetts . PAREXEL has additional locations in the United States and the United Kingdom . The company is actively operating and employs between 10,000 and 49,999 people, with a total of 18,900 employees .

PAREXEL is involved in various industries, including biotechnology, biology, digital health, clinical trials, telehealth, and decentralized clinical trials . The company has been assigned four patents and has formed strategic partnerships with organizations such as 54Gene .

The company is listed on the Nasdaq stock exchange under the symbol PRXL . PAREXEL is incorporated in Massachusetts and has a Standard Industrial Classification (SIC) code of 8731 . The company's Internal Revenue Service (IRS) number is 42776269, and its Central Index Key (CIK) number can be found on the U.S. Securities and Exchange Commission's website .

PAREXEL has received investments from Easton Capital and is a subsidiary of EQT Partners . The company's official website is https://parexel.com, and it can be contacted via email at info@parexel.com . PAREXEL is also active on social media platforms, including LinkedIn, Twitter, Facebook, and Instagram .